openPR Logo
Press release

Non-Small Cell Lung Cancer Therapeutics Industry – Asia-Pacific Market Forecast 2016-25 : Trend, Size, Share, Analysis, Growth, New Projects

06-15-2016 12:24 PM CET | Health & Medicine

Press release from: Researchmoz Global Pvt. Ltd.

Description - Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets

Non-Small Cell Lung Cancer (NSCLC) is the most common cancer and cause of cancer-related mortality globally. There were more than 1.8 million newly diagnosed lung cancer cases in 2012 globally, accounting for 13% of the total number of cancer cases. Over half of the incident cases of NSCLC are diagnosed in patients over the age of 65 - a high-risk age range for lung cancer. As the aged population is projected to increase, the prevalence of lung cancer is anticipated to increase, thereby acting as a driver for revenue growth. The poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The NSCLC market is undergoing a gradual change from a focus on generic chemotherapy regimens to a complex treatment landscape based on different NSCLC subtypes, and the presence of various molecular aberrations.

To Browse a Report Detail with TOC @ http://www.researchmoz.us/nonsmall-cell-lung-cancer-therapeutics-in-asiapacific-markets-to-2022-launch-of-premium-targeted-therapies-and-increasing-prevalence-to-drive-the-market-report.html

In the current market, patients with non-squamous histology can be treated with more efficacious therapies such as Alimta (pemetrexed), while patients harboring activating mutations in EGFR or ALK can be prescribed targeted therapies such as Tarceva, Iressa, Xalkori and Gilotrif. Opdivo (nivolumab) - a mAb immune checkpoint inhibitor targeted towards Programmed cell Death (PD) 1 - is a recent market entrant, gaining approval for treating advanced or metastatic squamous NSCLC patients in Japan in 2015 and in Australia in 2016. While the NSCLC developmental pipeline must aim to improve the outlook for all patients, there is currently a lack of options for patients with squamous cell histology or other detectable molecular characteristics besides EFGR and ALK mutations. Therapies that target mutant T790M and KRAS are being developed in the pipeline, with osimertinib, targeting T790M, gaining approval in Japan in 2016.

Scope

The NSCLC Asia-Pacific market will be valued at $4.9 billion in 2022, growing from $2.7 billion in 2015 at a CAGR of 8.7%.

How will immunotherapies such as Keytruda contribute to the growth?
What effect will patent expirations of currently branded therapies have on market value?

The NSCLC pipeline is large and diverse, with an increased presence of mAbs and targeted therapies.

What are the common targets and mechanisms of action of pipeline therapies?
Will the pipeline address unmet needs such as a lack of treatments for squamous cell patients?
What implications will the increased focus on targeted therapies have on the future of NSCLC treatment?

Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.

How have the late-stage therapies performed in clinical trials?
How would the approval of rociletinib to treat T790M mutant patients affect the competitive landscape, with its competitor osimertinib (AZD-9291) already approved in Japan in 2016?
How would the approval of abemaciclib to treat KRAS mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?

To Free Sample Report With TOC @ http://www.researchmoz.us/enquiry.php?type=S&repid=725317

The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.

How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?
How could changes in risk factors such as population age, smoking habits and pollution influence the market?

Licensing deals are the most common form of strategic alliance in NSCLC, with total deal values ranging from under $10m to over $1 billion.

How do deal frequency and value compare between target families and molecule types?
What were the terms and conditions of key licensing deals?

Reasons to buy

This report will allow you to -

Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
Visualize the composition of the NSCLC market in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
Analyze the NSCLC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
Predict NSCLC market growth in the five Asia-Pacific markets with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as individual contributions of promising late-stage molecules to market growth.
Identify commercial opportunities in the NSCLC deals landscape by analyzing trends in licensing and co-development deals.

Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 8

2 Introduction 10
2.1 Disease Introduction 10
2.2 Epidemiology 11
2.3 Symptoms 12
2.4 Etiology and Pathophysiology 13
2.4.1 Adenocarcinoma 14
2.4.2 Squamous-Cell Carcinoma 16
2.4.3 Large-Cell Carcinoma 19
2.4.4 Immunotherapy 20
2.5 Diagnosis 20
2.6 Prognosis 23
2.7 Treatment Guidelines and Options 23
2.7.1 Treatment Algorithm 24
2.7.2 First-Line Treatment 25
2.7.3 Maintenance Therapy 26
2.7.4 Second-Line Treatment 27
2.7.5 Third-Line Therapy 28
2.7.6 Adjuvant Therapy 29

3 Marketed Products 30
3.1 Overview 30
3.2 Chemotherapies 30
3.2.1 Alimta (pemetrexed) - Eli Lilly 30
3.2.2 Abraxane (paclitaxel) - Celgene 31
3.3 Tarceva (erlotinib) - Roche 32
3.4 Iressa (gefitinib) - AstraZeneca 33
3.5 Gilotrif (afatinib) - Boehringer Ingelheim 34
3.6 Xalkori (crizotinib) - Pfizer 35

To Enquire Regarding This Report @ http://www.researchmoz.us/enquiry.php?type=E&repid=725317

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Researchmoz Pvt. Ltd.,
90 State Street,
Albany, NY 12207,
United States,
Tel: 866-997-4948 (Us-Canada Toll Free),
Tel: +1-518-621-2074

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Non-Small Cell Lung Cancer Therapeutics Industry – Asia-Pacific Market Forecast 2016-25 : Trend, Size, Share, Analysis, Growth, New Projects here

News-ID: 344343 • Views: 484

More Releases from Researchmoz Global Pvt. Ltd.

Online Fitness Services Market Size, Share, Growth, Trend, Drivers and Restraint …
Online Fitness Services Market is predicted to grow at substantial compounded annual rate of growth (CAGR) during the forecast period 2020-2027. The markets growth is analysed by studying multiple determinants like Market Drivers, Trends, Challenges, Opportunities, Restraints, and Competition. It includes detailed analysis of the market on the basis of competitive profiles of key players, market segmentations, geographical analysis and economic models. The influence of Covid-19 on the market is discussed
Senior Living Market Current Status and Challenges with Future Opportunities to …
The Senior Living Market Report provides a detailed assessment of the market by highlighting information on various aspects including the global market, including drivers, restraints, opportunities, threats and development trends, competitive landscape analysis, and Growth status of key regions. The report provides comprehensive numerical analysis of the Senior Living industry and data for creating strategies to increase market growth and success. The report estimates market size, price, revenue, gross margin
Testing and Inspection Services Market 2020 Analysis includes Growth, Challenges …
The Testing and Inspection Services Market Report provides a detailed assessment of the market by highlighting information on various aspects including the global market, including drivers, restraints, opportunities, threats and development trends, competitive landscape analysis, and Growth status of key regions. The report provides comprehensive numerical analysis of the Testing and Inspection Services industry and data for creating strategies to increase market growth and success. The report estimates market size,
Proctoring Solution for Online Exams Market 2021 Leading Players, Industry Updat …
The study provides an in-depth study of the Proctoring Solution for Online Exams Market's trends and opportunities. On the basis of recent events and historical data, it makes figurative estimates and forecasts the future for the coming years. Moreover, the market document holds a substantial importance when it is about explaining market definition, classifications, applications and engagements. With the study of competitor analysis conducted in this Proctoring Solution for Online

All 5 Releases


More Releases for NSCLC

Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size, Status and Forec …
Market Research Report Store offers a latest published report on Targeted Drug EGFR RTK Inhibitors for NSCLC Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. The report contains 158 pages which highly exhibit on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability. Click to view the full report TOC, figure and tables: https://www.marketresearchreportstore.com/reports/624297/global-targeted-drug-egfr-rtk-inhibitors   In 2018,
Targeted Drugs for NSCLC Market Size by 2025: QY Research
Global Targeted Drugs for NSCLC market report is first of its kind research report that covers the overview, summary, market dynamics, competitive analysis, and leading player’s various strategies to sustain in the global market. This report covers five top regions of the globe and countries within, which shows the status of regional development, consisting of market value, volume, size, and price data. Apart from this, the report also covers detail
"NSCLC - Market Outlook and Competitive Landscape Report 2015 – 2030 "
Report Snapshot: NSCLC is the most common form of lung cancer, accounting for approximately 85% of all types and subtypes of lung cancer. It grows and spreads more slowly than small cell lung cancer. Early stage disease is associated with uncommon specific symptoms; hence roughly ~50% to 73% of cases are not being diagnosed until the disease is at an advanced stage when the chances for cure or significant patient benefit
Non-Small Cell Lung Cancer (Nsclc)-China Drug Forecast and Market Analysis To 20 …
Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva
PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast And Marke …
Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva
The NSCLC Market Will Be Valued At $10.9 Billion In 2021 At A CAGR Of 8.5%
Researchmoz added Most up-to-date research on "Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to 2021 - Emergence of Immunotherapies Drives Market Growth and Creates A Competitive Second-Line" to its huge collection of research reports. Non-Small Cell Lung Cancer (NSCLC) is the second most common cancer globally, and the most common cause of cancer-related mortality. Such a poor outlook, particularly for patients with advanced disease, has created a pressing need